Genus (LON:GNS) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Shares of Genus plc (LON:GNSGet Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 1,801.25 ($23.27) and traded as high as GBX 1,914 ($24.73). Genus shares last traded at GBX 1,901.92 ($24.58), with a volume of 5,376,931 shares trading hands.

Wall Street Analyst Weigh In

Separately, Shore Capital reissued a “buy” rating on shares of Genus in a research note on Wednesday, December 11th.

Get Our Latest Analysis on GNS

Genus Trading Down 0.1 %

The company has a market cap of £1.25 billion, a PE ratio of 157.65, a price-to-earnings-growth ratio of 2.87 and a beta of 0.37. The business has a 50 day simple moving average of GBX 1,743.87 and a two-hundred day simple moving average of GBX 1,802.60. The company has a current ratio of 1.80, a quick ratio of 1.08 and a debt-to-equity ratio of 53.12.

Genus (LON:GNSGet Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.51) earnings per share for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, analysts forecast that Genus plc will post 70.9644323 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Jorgen Kokke sold 19,967 shares of the company’s stock in a transaction on Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($22.37), for a total transaction of £345,628.77 ($446,606.50). Corporate insiders own 0.75% of the company’s stock.

About Genus

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Read More

Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.